EFFECT OF RIVASTIGMINE

Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment - Full Text View - ClinicalTrials.govThis study will evaluate the efficacy and safety of 10 cm rivastigmine patch vs. placebo in cognitively impaired Multiple Sclerosis (MS) patients.Primary objective is the assessment of cognition by the Selective Reminding Test (SRT) -a subtest of the brief repeatable battery (BRB) - after titration of 4 weeks and maintenance of 12 weeks. This double-blind period will be followed by a 52-week open-label treatment phase to assess long-term safety of rivastigmine patch in these patients.